W Michael Korn

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition
    Neda Bagheri
    Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
    PLoS Comput Biol 7:e1001085. 2011
  2. pmc Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma
    Olga K Mirzoeva
    Corresponding Author W Michael Korn, UCSF Divisions of Gastroenterology and Hematology Oncology, Helen Diller Family Comprehensive Cancer Center, 2340 Sutter St, Box 1387, San Francisco, CA 94115
    Mol Cancer Ther 12:2213-25. 2013
  3. pmc ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor
    Markus D Lacher
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, CA, USA
    Mol Cancer 10:91. 2011
  4. doi request reprint A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H Ko
    University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 66:1051-7. 2010
  5. ncbi request reprint Prevention and management of early esophageal cancer
    W Michael Korn
    University of California, 2340 Sutter Street, San Francisco, CA 94115, USA
    Curr Treat Options Oncol 5:405-16. 2004
  6. ncbi request reprint Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells
    Mario Anders
    Cancer Research Institute, University of California, San Francisco 94143, USA
    Cancer Res 63:2088-95. 2003
  7. pmc Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition
    Olga K Mirzoeva
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, California 94115, USA
    Cancer Res 69:565-72. 2009

Collaborators

  • Eric A Collisson
  • Byron Hann
  • Emily K Bergsland
  • Alan P Venook
  • Joe W Gray
  • Olga K Mirzoeva
  • Andrew H Ko
  • Marisa Shiina
  • Neda Bagheri
  • Markus D Lacher
  • Frank McCormick
  • Mario Anders
  • Yun K Hom
  • Peter M Schaefer
  • Peter Chang
  • Maarit I Tiirikainen
  • Douglas A Lauffenburger
  • Debora Keller
  • Margaret A Tempero
  • R Kate Kelley
  • Elizabeth Dito
  • Brian Schillinger
  • Jimmy Hwang
  • Janet Scott
  • Debopriya Das
  • Philippe Gascard
  • Paul T Spellman
  • Laura M Heiser
  • Mina J Bissell
  • Nora Bayani
  • Sanchita Bhattacharya
  • Andrew J Wyrobek
  • Zhi Hu
  • Gordon B Mills
  • Heidi S Feiler
  • Kevan M Shokat
  • Rina Gendelman
  • Bahram Parvin
  • Doris Siwak
  • Yinghui Guan
  • Wen Lin Kuo
  • Richard M Neve
  • Zachary Knight
  • Nicholas J Wang
  • Christine Christian
  • Martin McMahon

Detail Information

Publications7

  1. pmc A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition
    Neda Bagheri
    Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
    PLoS Comput Biol 7:e1001085. 2011
    ..Enhanced oncolytic therapy has the potential to dramatically improve non-surgical cancer treatment, especially in locally advanced or metastatic cases where treatment options remain limited...
  2. pmc Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma
    Olga K Mirzoeva
    Corresponding Author W Michael Korn, UCSF Divisions of Gastroenterology and Hematology Oncology, Helen Diller Family Comprehensive Cancer Center, 2340 Sutter St, Box 1387, San Francisco, CA 94115
    Mol Cancer Ther 12:2213-25. 2013
    ..Thus, our findings suggest a new, subtype-specific, and personalized therapeutic strategy for pancreatic cancer...
  3. pmc ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor
    Markus D Lacher
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, CA, USA
    Mol Cancer 10:91. 2011
    ..While EMT is crucial in embryonic development, it has been proposed to contribute to the formation of invasive and metastatic carcinomas by reducing cell-cell contacts and increasing cell migration...
  4. doi request reprint A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H Ko
    University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 66:1051-7. 2010
    ..Based on potential for additive or synergistic activity by concurrent inhibition of VEGF and EGFR, we conducted a phase II study evaluating the combination of bevacizumab plus erlotinib in this patient population...
  5. ncbi request reprint Prevention and management of early esophageal cancer
    W Michael Korn
    University of California, 2340 Sutter Street, San Francisco, CA 94115, USA
    Curr Treat Options Oncol 5:405-16. 2004
    ..For patients with adenocarcinoma of the gastroesophageal junction with submucosal involvement, adjuvant chemoradiation should be considered because of its potential to increase survival...
  6. ncbi request reprint Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells
    Mario Anders
    Cancer Research Institute, University of California, San Francisco 94143, USA
    Cancer Res 63:2088-95. 2003
    ....
  7. pmc Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition
    Olga K Mirzoeva
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, California 94115, USA
    Cancer Res 69:565-72. 2009
    ....